ZA201902595B - Structures and mechanism for the design of highly potent glucocorticoids - Google Patents

Structures and mechanism for the design of highly potent glucocorticoids

Info

Publication number
ZA201902595B
ZA201902595B ZA2019/02595A ZA201902595A ZA201902595B ZA 201902595 B ZA201902595 B ZA 201902595B ZA 2019/02595 A ZA2019/02595 A ZA 2019/02595A ZA 201902595 A ZA201902595 A ZA 201902595A ZA 201902595 B ZA201902595 B ZA 201902595B
Authority
ZA
South Africa
Prior art keywords
structures
design
highly potent
potent glucocorticoids
glucocorticoids
Prior art date
Application number
ZA2019/02595A
Other languages
English (en)
Inventor
Eric Xu Huaqiang
He Yuanzheng
Original Assignee
Van Andel Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Van Andel Res Institute filed Critical Van Andel Res Institute
Publication of ZA201902595B publication Critical patent/ZA201902595B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2019/02595A 2016-10-14 2019-04-24 Structures and mechanism for the design of highly potent glucocorticoids ZA201902595B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408314P 2016-10-14 2016-10-14
PCT/US2017/056447 WO2018071736A1 (en) 2016-10-14 2017-10-13 Structures and mechanism for the design of highly potent glucocorticoids

Publications (1)

Publication Number Publication Date
ZA201902595B true ZA201902595B (en) 2021-04-28

Family

ID=61906432

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/02595A ZA201902595B (en) 2016-10-14 2019-04-24 Structures and mechanism for the design of highly potent glucocorticoids

Country Status (12)

Country Link
US (1) US10954265B2 (enExample)
EP (1) EP3525870B1 (enExample)
JP (2) JP7146750B2 (enExample)
KR (1) KR102497070B1 (enExample)
CN (1) CN110382033B (enExample)
ES (1) ES2945983T3 (enExample)
MA (1) MA46539A (enExample)
PH (1) PH12019500801A1 (enExample)
RU (1) RU2019111101A (enExample)
SG (1) SG11201903209TA (enExample)
WO (1) WO2018071736A1 (enExample)
ZA (1) ZA201902595B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024396409A1 (en) * 2023-12-08 2026-07-09 Zhejiang Palo Alto Pharmaceuticals, Inc. High-efficacy glucocorticoid polymorph, preparation method therefor, and use thereof
WO2025157225A1 (zh) * 2024-01-24 2025-07-31 浙江柏拉阿图医药科技有限公司 一种高效力糖皮质激素化合物及其制备和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK66202C (da) 1945-03-03 1948-01-12 Danske Securitas As Kodekontakt til elektriske Alarmanlæg.
DK71662C (da) 1946-09-05 1950-11-06 Ingenioer Frank Broadbent Tørrecentrifuge.
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
US5837698A (en) * 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
WO2002102807A1 (en) 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
KR20060118536A (ko) * 2003-11-13 2006-11-23 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료 방법 및 시약
KR20080039442A (ko) * 2005-09-02 2008-05-07 니콕스 에스. 에이. 스테로이드 니트록시 유도체들
CN1813768A (zh) * 2005-11-18 2006-08-09 成都力思特制药股份有限公司 治疗呼吸系统疾病的药用组合物及其在制药中的应用
MX2010003698A (es) * 2007-10-04 2010-04-21 Astrazeneca Ab Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
US20110160167A1 (en) * 2007-12-20 2011-06-30 Astrazeneca Ab Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists
US8173670B2 (en) 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
TW201111392A (en) * 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
HK1222565A1 (zh) * 2013-09-25 2017-07-07 范安德尔研究所 高效糖皮質激素
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Also Published As

Publication number Publication date
KR20190068577A (ko) 2019-06-18
WO2018071736A9 (en) 2019-05-23
CN110382033B (zh) 2022-04-15
RU2019111101A (ru) 2020-11-16
ES2945983T3 (es) 2023-07-11
JP2022132464A (ja) 2022-09-08
EP3525870A4 (en) 2020-04-29
CN110382033A (zh) 2019-10-25
US20190263853A1 (en) 2019-08-29
JP2019532071A (ja) 2019-11-07
US10954265B2 (en) 2021-03-23
EP3525870B1 (en) 2023-05-10
WO2018071736A1 (en) 2018-04-19
KR102497070B1 (ko) 2023-02-06
JP7146750B2 (ja) 2022-10-04
SG11201903209TA (en) 2019-05-30
EP3525870A1 (en) 2019-08-21
RU2019111101A3 (enExample) 2020-11-27
PH12019500801A1 (en) 2019-11-11
MA46539A (fr) 2019-08-21

Similar Documents

Publication Publication Date Title
IL266353A (en) Steroids and their protein conjugates
EP3468973A4 (en) SOLID FORMS OF VENETOCLAX AND METHOD FOR PRODUCING VENETOCLAX
IL265628A (en) Solid state forms of valbenazine
HUE062956T2 (hu) Eljárások niraparib és köztitermékei elõállítására
PT3458467T (pt) Processo para a epoxidação 6,7-alfa de esteroide-4,6-dienos
IL259391B (en) Hydroxamate triterpenoid derivatives
PL3335983T3 (pl) Statek powietrzny
ZA202000970B (en) Pentacyclic compound
GB2549996B8 (en) Structures
ZA201900843B (en) Isolating transformer
LT3548016T (lt) Ror-gama (rory) moduliatoriai
IL255819A (en) An improved process for the preparation of sofosbuvir and intermediates
SG10202108899XA (en) Anti-inflammatory agent
HUE071989T2 (hu) Új intermedierek 11-metilén-szteroidok elõállítására
MA46539A (fr) Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
GB201619846D0 (en) Saponin composition
IL263789A (en) Purified cenicriviroc and purified intermediates for making cenicriviroc
SG10201705861SA (en) Process for the alkoxycarbonylation of ethers
EP3474847A4 (en) OXAZOLDINONE PREPARATION METHODS.
PT3414211T (pt) Composição de reboco
IL258573A (en) Inhibitor of the p2x7 receptor
PT3445377T (pt) Composições para a pele
AU2016904557A0 (en) Devices for Enhancing the Boardding of Aircraft
GB2587294B (en) Processes for the preparation of desflurane